


SUPPLEMENTARY FIGURES



Supplementary Figure 1. TP73-AS1 is highly expressed in GBM tumors of aged patients. (A) The levels of *TP73-AS1* in GBM tumors obtained form the old vs. young patients are shown. Data were obtained from GBM-US donors (a total of 595 donors) from ICGC database [1]. (B) The correlation between the expression of *TP73-AS1* and age in the tumors of GBM patients. Data were obtained from GBM-US donors (a total of 595 donors) from ICGC database [1].



Supplementary Figure 2. YY1 and TP73-AS1 are co-expressed in GBM and aging brain. (A) The correlation between the expression of *TP73-AS1* and *YY1* in the GBM were determined using R2 and TCGA dataset. (B) The correlation between the expression of *TP73-AS1* and *YY1* across different brain parts in the GTEx dataset. (C) The correlation between the expression of *TP73-AS1* and *YY1* in aging brain were determined using R2 and the indicated datasets. (D) The correlation between the expression of *TP73-AS1* and *p73* in the aging were determined using R2 and indicated dataset.



Supplementary Figure 3. TMZ does not induce YY1 at the protein level. The indicated cells treated or not with TMZ for 3 days after which the levels of YY1 in the total cell lysate or chromatin fraction were measured using western blot. Ponceau S was used to determine total protein loading.

REFERENCES

 Zhang J, Bajari R, Andric D, Gerthoffert F, Lepsa A, Nahal-Bose H, Stein LD, Ferretti V. The International Cancer Genome Consortium Data Portal. Nat Biotechnol. 2019; 37:367–69. <u>https://doi.org/10.1038/s41587-019-0055-9</u> PMID:<u>30877282</u>